Clinical Trial Search

Primary: Percentage of Participants Maintaining CR-SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both…

Primary: Pembro Combo vs Control: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review…

Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 3.0; 2.8 Months — p=0.0186

Primary: Change in HbA1c — -0.9; -1.3; -1.5; -0.3 Percentage of HbA1c — p=<0.0001

Primary: Participants Who Achieve HbA1c <7.0% (53 mmol/Mol) ADA Target (Yes/no) — 134; 60; 96; 178 Participants — p=<0.0001

Primary: Time to First Clinical Worsening Event — 60.58; 49.31 weeks — p=0.0275

Primary: Tuberculose Treatment Outcome — 8; 8; 11; 5 Participants

Primary: Postoperative Pain Experience — 78.6; 105.2 score on a scale* hour

Primary: Change From Baseline in Pre-dose FEV1 at Week 12 — 0.112; 0.071 Liters — p=0.088

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 in the Study Eye — 2.1 ETDRS Letters

Primary: Absolute Change in Lung Clearance Index 2.5 (LCI2.5) Through Week 8 — -0.51 lung clearance index — p=<0.0001

Primary: Annualized Rate of Porphyria Attacks in Participants With Acute Intermittent Porphyria (AIP) — 12.52; 3.22 annualized attack rate — p=<0.0001

Primary: Proportion of Subjects With Anti-rabies Antibody Titer of ≥0.5 IU/mL — 73; 72 Participants — p=0.0006

Primary: Change From Baseline in Mean Latency to Persistent Sleep (LPS) of Lemborexant 10 mg and Lemborexant 5 mg Compared to Placebo on Days 29/30 — 43.89; 44.86; 44.61; -7.93…

Primary: Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure — -0.925; -0.896 score on a scale — p=0.881